Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric maltol vs ferrous sulfate in pediatric iron-deficiency anemia
NCT05126901Phase 3Completed
- Sponsor
- Shield Therapeutics plc
- Start
- Nov 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of ferric maltol in iron deficiency anemia (IDA), sponsored by Shield Therapeutics plc. Started Nov 2021; status: completed.
02
Drugs
ferric maltol
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT05126901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05126901.